ISSN: xxxx-xxxx (online) / ISSN: xxxx-xxxx (print)
The “Middle Eastern Cancer and Oncology Journal (MECOJ)” is an online, peer-reviewed, open access journal that strives to push the boundaries of oncology by enhancing the understanding of cancer biology, evolving treatment methods, and effective prevention strategies. It is established in 2025 by OncoEval Pioneers Group and owned by Scientific Steps International Publishing Services which owns the copyright and licensing for all issues and articles in the journal. MECOJ serves as a critical platform for the swift publication of pioneering research that connects the intricate scientific findings with tangible clinical applications. The journal champions the exploration of innovative therapeutic approaches and groundbreaking genetic discoveries that redefine cancer care standards globally. Emphasizing both regional challenges in the Middle East and global advancements, the journal aims to foster collaborative insights that enhance cancer research and treatment outcomes worldwide.
The “Middle Eastern Cancer and Oncology Journal (MECOJ)” is published biannually, providing a platform for the timely dissemination of high-quality research in the field of oncology. The journal publishes different types of articles in English, including original research articles, case reports, and review articles across all areas of oncology. This frequency allows for thorough peer review and ensures that each issue meets the journal’s standards for academic excellence. The peer-review process is designed to be efficient yet rigorous, typically taking between 30 to 60 days from submission to decision. As the journal grows and gains traction, we may consider increasing the frequency of publication based on the volume of high-quality submissions received.
The MECOJ is recognized by the Iraqi Society of Clinical Oncology (ISCO)
MECOJ welcomes a broad spectrum of contributions from the field of oncology, including but not limited to research, reviews, and clinical studies in oncology, with a focus on topics such as cancer biology, clinical treatments, genomics, translational research, public health, and innovative technologies. The scope is designed to encapsulate a comprehensive range of topics that reflect the dynamic nature of oncological research and its application, ensuring MECOJ’s role as a nexus for scholarly and clinical expertise that drives significant advancements in the field.
The “Middle Eastern Cancer and Oncology Journal (MECOJ)” invites a broad range of contributions across various domains of oncology. The topics include, but are not limited to:
1- The Middle Eastern Cancer and Oncology Journal (MECOJ) is an internationally recognized publication in the field of cancer and oncology. This scientific journal features peer-reviewed, open access articles and is published biannually by SCIENTIFIC STEPS INTERNATIONAL PUBLISHING SERVICES L.L.C.
2- Determine the type of article you wish to submit:
3- Ensure the originality of your manuscript by checking it for plagiarism using a plagiarism checker. The maximum similarity rate allowed in the Middle Eastern Cancer and Oncology Journal (MECOJ) is 20%. Additional information regarding publishing ethics, including plagiarism, can be found in the Publication Ethics.
4- Prepare your manuscript using the Microsoft Word Template
5- Submit your manuscript online through the Submission Website. The submitting author, who is typically the corresponding author, is responsible for the manuscript during the submission and peer-review process. The submitting author must confirm that all eligible co-authors have been included in the author list and have approved the submitted version of the manuscript. All co-authors can view the manuscript details in the submission system by registering and logging in using the email address provided during manuscript submission.
6- Manuscript presentation:
6.1- Formatting a Manuscript for Submission
a. Writing Style: Manuscripts must be written in clear, concise English and should be typed using a Times New Roman font, size 12 pt. Please use 1.5 line spacing for all materials. The total length of the paper, including text, tables, and figures, should not exceed 25 pages. Tables and figures should be placed within the text.
b. Formatting: Manuscripts should include line numbers and page numbers but should not include headers, footers, notes, or footnotes. The final manuscript file size should not exceed 5 MB.
c. Scientific Ethics: The manuscript should follow ethical standards in scientific writing, including:
6.2- Manuscript Structure
a. Title Page
The title page should include the following elements:
b. Main Text
Original Investigations and Brief Reports typically comprise five sections: Introduction, Materials, Methods, Results, and Discussion.
The discussion begins with an overview of the work and a summary of the key findings. It uses the results to describe each studied effect, construct arguments for or against hypotheses, or address the main objectives of the study. The discussion delves into the principles, relationships, and generalizations demonstrated by the results, pointing out exceptions, lack of correction, and defining unsettled points. The author’s interpretations are presented, emphasizing the broader implications and significance of the findings.
The conclusion should not merely repeat information from the Results and Discussion sections but should offer insightful commentary on the significance and implications of the findings. The final paragraph of the conclusion should provide recommendations for future research, suggesting areas where further investigation is needed or proposing new lines of inquiry based on the study’s outcomes.
Conclusions should be written in descriptive paragraph form. Avoid using bulleted lists.
This section gives appreciation to individuals and organizations that provide assistance to the author. Acknowledgments to sponsors and financial support are also included in this section.
For full articles, authors are required to include a minimum of 30 references, while review articles must have at least 60 references. Self-citations should not exceed 10% of the total references. There are no specific reference limits for other types of submissions, such as case studies, letters, and opinion pieces.
Examples of different reference types include:
Journal Articles
Books
Book Chapters
Regulations and Laws
Theses
Internet Sources
7- Final checklist before submission
Before submitting the manuscript for publication, authors must meticulously ensure the following details are addressed:
All articles published in The Middle Eastern Cancer and Oncology Journal (MECOJ) are published in full open access. All articles published in MECOJ are published in full open access. We are pleased to announce that at present, there are No Publishing Fees for submissions. This temporary policy allows authors to publish their work free of charge.
Submitted papers should be well formatted and use good English. Authors may use SSG’s English editing service prior to publication or during author revisions.
You can read more about Article Processing Charges (APC) of SSG’s Journals.
The MECOJ journal, under SSG’s publication, follows an Open-Access model for articles published within it. These articles are disseminated in accordance with the Creative Commons Attribution License (CC BY). Authors retain the copyright for their published work.
Upon publication, MECOJ will include the following statement at the conclusion of the article:
“Copyright: © year of publication by the authors. Licensee SSG, Dubai, UAE.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND 4.0) license (http://creativecommons.org/licenses/by-nc-nd/4.0/).“
This note signifies that the published article is open access and governed by the CC BY license, allowing readers to access, distribute, and build upon the content while acknowledging the original authors.
Research Involving Human Subjects:
Ethical Guidelines for Animal Research:
Research Involving Cell Lines:
Research Involving Plants:
Clinical Trials Registration:
Dual Use Research of Concern:
Sex and Gender in Research:
Borders and Territories:
Authors are required to adhere to strict guidelines regarding citation practices to ensure academic integrity and proper attribution of sources.
In line with the Committee on Publication Ethics (COPE) guidelines, direct quotations from other researchers’ work, including the author’s own, should be appropriately marked within quotation marks and cited. COPE has issued a discussion document on citation manipulation, offering recommendations for best practices.
MECOJ expects authors to strictly adhere to these citation policies to maintain the scholarly integrity of published work. These guidelines aim to promote fairness, transparency, and ethical citation practices within academic research and publishing.
Editor in Chief: Dr. Bassam Abdul Rasool Hassan
PhD Clinical Pharmacy, USM, Malaysia
Al-Rafidain University, Iraq
Prof. Dr. Hadi Skouri: Consultant Cardio-Oncology, Shiekh Shakboot Medical City, UAE
Dr. Musaab Kadhim: Medical Oncology Department, Alamal National Hospital for Cancer Treatment, Baghdad, Iraq.
Supervisor in the Arabic Board.
Dr. Hayder Jaber: President of Oncology Fellowship Council, Arabic Board, Director of the Middle Al Forat Center of Oncology.
Dr. Noufel Shakir: Vice President of Surgical Oncology Fellowship Council, Arabic Board, Medical City Complex, Baghdad, Iraq.
Dr. Noor Rafie: Nuclear Medicine Department, Alamal National Hospital for Cancer Treatment, Baghdad, Iraq.
Trainer in the Arabic Board.
Dr. Sabbar Shukri: Radiotherapy Department, Alamal National Hospital for Cancer Treatment, Baghdad, Iraq.
Member and Trainer in both the Iraqi and the Arabic Radiation Oncology Boards.
Dr. Haidar Kadhim: Clinical Pharmacy department, Ministry of Health, Baghdad, Iraq.
Dr. Vladimir Startsev: Professor of Oncology Department of St. Petersburg state pediatric medical university, St. Petersburg, Russia
Dr. Chema Drira: Associate Professor, Head of Pharmacy Department, National Marrow Bone Transplant Center of Tunisia, Ariana, Tunisia
Analytical Chemistry Department, Faculty of Pharmacy Monastir, Monastir, Tunisia.
Dr. Said Nabil: Tawam Hospital, Pharmacy Department, United Arab Emirates.
Dr. Zohour Anouassi, United Arab Emirates.
Dr. Muhamad Faiz Othman: Department of Pharmacy, UiTM, Malaysia.
Dr. Khalid Al-Baimani: Senior Consultant Medical Oncologist, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City.
Dr. Luqman Rahman Sulaiman: Assistant Professor, Consultant Oncologist, Department of Medicine, College of Medicine, Hawler Medical University.
Dr. Mazin Judy Ibrahim: Licensed Specialist Medical Oncology, Burjeel Medical City, Burjeel Cancer Institute, Al-Dhannah Hospital Abu Dhabi/ United Arab Emirates, Committee member of Iraqi Board Medical Oncology,
Assistant Professor, Medical Department, College of Medicine, University of Baghdad.
Dr. Humam Alkhaled, PharmD, Pharmacy Clinical Specialist Hematology, Bone Marrow Transplant, Georgetown University Hospital
Dr. Juman Ali Abdulelah
PhD Clinical Pharmacy, USM, Malaysia
Swansea University, UK
Dr. Muna Mojahed Barakat
PhD Physiology and Therapeutic Immunology, Queen’s University Belfast, UK
Applied science private university, Jordan
Dr. Diana Malaeb
PhD Pathology and Clinical Research, Universite Paris-Est Creteil, France
Gulf Medical University, UAE
Dr. Angelina Lim
PhD Clinical Pharmacy, Monash University, Australia.
Monash University, Australia.
Dr. Ahmed Zuhair Abdulhameed
Medical Oncology Department, Oncology Teaching Hospital Baghdad, Iraq.
Dr. Ali Haider Mohammed
MSc Clinical Pharmacy, UiTM, Malaysia
Monash University, Malaysia
An independent academic publisher with an editorial team including many of the top researchers in the world. SSG publishes research, review, and case report articles in double-blind, peer-reviewed, open access scientific and academic journals.
Copyright © 2023 Scientific Steps International Publishing Services LLC (Dubai – United Arab Emirates)